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Background: The burden on caregivers of patients with Alzheimer’s disease (AD) is associated with the patient’s
functional status and may also be influenced by chronic comorbid medical conditions, such as diabetes. This post-
hoc exploratory analysis assessed whether comorbid diabetes in patients with AD affects caregiver burden, and
whether caregivers with diabetes experience greater burden than caregivers without diabetes. Caregiver and
patient healthcare resource use (HCRU) were also assessed.
Methods: Baseline data from the GERAS observational study of patients with AD and their caregivers (both n =
1495) in France, Germany and the UK were analyzed.
Caregiver burden was assessed using the Zarit Burden Interview (ZBI). Caregiver time on activities of daily living
(ADL: basic ADL; instrumental ADL, iADL) and supervision (hours/month), and caregiver and patient HCRU
(outpatient visits, emergency room visits, nights hospitalized) were assessed using the Resource Utilization in
Dementia instrument for the month before the baseline visit. Regression analyses were adjusted for relevant
covariates. Time on supervision and basic ADL was analyzed using zero-inflated negative binomial regression.
Results: Caregivers of patients with diabetes (n = 188) were younger and more likely to be female (both p < 0.05),
compared with caregivers of patients without diabetes (n = 1307). Analyses showed caregivers of patients with
diabetes spent significantly more time on iADL (+16 %; p = 0.03; increases were also observed for basic ADL and
total caregiver time but did not reach statistical significance) and had a trend towards increased ZBI score. Patients
with diabetes had a 63 % increase in the odds of requiring supervision versus those without diabetes (p = 0.01).
Caregiver and patient HCRU did not differ according to patient diabetes.
Caregivers with diabetes (n = 127) did not differ from those without diabetes (n = 1367) regarding burden/time, but
caregivers with diabetes had a 91 % increase in the odds of having outpatient visits (p = 0.01).
Conclusions: This cross-sectional analysis found caregiver time on iADL and supervision was higher for caregivers
of patients with AD and diabetes versus without diabetes, while HCRU was unaffected by patient diabetes.
Longitudinal analyses assessing change in caregiver burden over time by patient diabetes status may help clarify
the cumulative impact of diabetes and AD dementia on caregiver burden.
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Alzheimer’s disease (AD) is the most common cause of
dementia, accounting for 60–80 % of dementia cases,
and prevalence increases with age [1]. In 2012, dementia
was estimated to affect 8.4 million people aged ≥60 years
in the European Union (EU), approximately 7 % of this
age group [1]. Although incidence rates vary, AD preva-
lence is generally consistent between European countries
and the USA [2].
People with AD have been reported to be at increased
risk of developing diabetes [3], and people with diabetes
are at increased risk of developing cognitive impairment
and AD dementia [4–7]. Around 60 million people in
Europe, ~8–10 % of the adult population, have diabetes or
impaired glucose tolerance [8, 9]. Estimates of the preva-
lence of diabetes in people with dementia range between 6
and 39 % [10], although most studies reviewed by Bunn
et al. [10] found no increase in diabetes prevalence for
people with versus without dementia (one study suggested
a lower prevalence of diabetes in hospitalized people with
dementia [11]). The risk of diabetes increases with longev-
ity [8, 9]; recent US data suggest a diabetes prevalence of
26 % (diagnosed and undiagnosed) in people aged 65 years
and over [12]. Predictions of increasing prevalence of both
dementia [13] and diabetes [8, 9, 14] are therefore based
on a future aging population.
In addition to shared demographics (e.g., aging, comor-
bidities, and genetic factors), there are reports of common
pathologies that link AD and diabetes, such as amyloid de-
posits, cardiovascular risk factors, inflammation, glucose
toxicity, and changes in insulin metabolism [6, 15–17]. Al-
though cardiovascular risk factors are more pathophysio-
logically relevant to vascular dementia than AD, they can
affect the rate of cognitive decline in AD dementia [6].
As AD dementia and diabetes are both chronic age-
related diseases, caregivers of affected patients experience
substantial burden [18, 19]. Burden may be influenced by
several factors, and can include both objective burden,
such as the amount of time spent helping the patient, and
the subjective burden perceived by the caregiver, as mea-
sured using the Zarit Burden Interview (ZBI; [20]).
In AD dementia, caregiver burden is associated with
the functional status of the patient [21] and may also be
related to chronic comorbid medical conditions, such as
diabetes. A small focus group study with 21 caregivers of
patients with dementia and type 2 diabetes reported that
caring for patients with both conditions is associated
with a high level of caregiver burden [22]. However,
there are contrasting reports about the weight of the
burden on those caring for patients with AD dementia
or diabetes among elderly populations. While diabetes
was not shown to be an independent predictor of burden
in caregivers of community-dwelling frail elderly patients
[23], a study by Langa and colleagues reported diabetes asa factor in increasing caregiver burden [24]. Dementia pa-
tient comorbidities and dependence are also associated
with increased caregiver healthcare resource use (HCRU)
and costs [25].
Caregiver burden and HCRU may also be related to the
health and functional status of the caregiver; caregivers
are often of a similar age to the patient and have various
medical conditions. Caregivers with medical conditions of
their own, such as diabetes, may experience greater bur-
den than those without such conditions, due to the added
responsibility of caring for the patient with AD dementia
alongside managing their own treatment. Differences in
social support given to caregivers may also affect caregiver
time and perceived burden [26]. Identifying factors that
influence burden and HCRU may help to inform possible
support measures for patients and caregivers.
GERAS is a prospective observational study of
community-dwelling patients with AD and their informal
caregivers in three European countries: France, Germany,
and the UK [27]. This post-hoc exploratory analysis
assessed whether caregiver burden among GERAS partici-
pants was affected by the presence of comorbid diabetes
in patients with AD, and whether caregivers with diabetes
experienced greater burden than caregivers without dia-
betes. The effect of diabetes status on caregiver and pa-
tient HCRU was also evaluated.Methods
Study design
GERAS is a large 18-month multicenter, prospective obser-
vational study designed to assess the costs and resource use
associated with AD for patients and their primary care-
givers in France, Germany, and the UK. Full details of the
study design and baseline findings [27], and an assessment
of the effects of AD dementia progression on costs and
caregiver-related outcomes at 18 months [28], have been
reported previously. The present analysis was restricted to
data from the baseline visit.
The study included community-dwelling patients aged
≥55 years, presenting during the normal course of care,
diagnosed with probable AD according to the National
Institute of Neurological and Communicative Disorders
and Stroke and Related Disorders Association criteria
[29], and with a Mini-Mental State Examination (MMSE)
score [30] of ≤26 points. Each patient also had to have an
informal (i.e., non-professional) caregiver who was willing
to take responsibility for the patient for at least 6 months of
the year (primary caregiver) and to participate in the study.
Ethical review board approval of the study was obtained in
each country according to individual country regulations.
Written informed consent was obtained from both the pa-
tient (or the patient’s legal representative; patients were
asked to give at least co-consent where able) and caregiver.
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severity at baseline as reported previously [27]: mild
(MMSE score 21–26 points), moderate (MMSE 15–20
points), or moderately severe/severe AD dementia
(MMSE <15 points). The GERAS study aimed to
recruit a minimum of 600 patients in each country (in
similar proportions of 200 in each severity group) to
obtain a 95 % confidence interval (CI) of ±10 % of the
mean cost estimate (based on the assumptions de-
scribed in Wimo et al. [27]). The primary analysis re-
ported here is based on the total AD dementia severity
population (MMSE ≤26 points). Secondary analyses
were performed based on the subgroup with mild/mod-
erate AD dementia (MMSE 16–26 points; consistent
with the MMSE criteria for patients included in the first
two phase 3 studies of solanezumab treatment [31]).
Patients enrolled in GERAS and their caregivers were
both queried at baseline regarding whether they suffered
from a list of common medical conditions, including
diabetes (information regarding patient medical condi-
tions could be provided by the patient or caregiver). For
this study, anyone positively endorsing “diabetes” was
considered to have diabetes. Apart from whether or not
diabetes medication was being received (Yes/No), no fur-
ther diabetes-related information, e.g., regarding diabetes
or medication type, or glycemic control, was requested.
Measures of caregiver burden
Both subjective and objective measures of burden were
considered in this analysis. Subjective caregiver burden
was assessed using the shortened 22-item version of the
original 29-item ZBI [20]. The ZBI provides a recog-
nized measure of the amount of subjective burden per-
ceived by the caregiver and is a valid, reliable and widely
recognized measure of caregiver burden [21, 32]. It is a
self-report inventory administered to the caregiver dur-
ing an assessment interview. Caregivers are asked to rate
their feelings regarding their health and psychological
wellbeing, finances, social life, and relationship with the
patient. Responses are used to derive the ZBI total score
(score range 0–88), where higher scores represent
greater burden.
Objective burden, i.e., caregiver time spent looking
after the patient, was assessed using the Resource
Utilization in Dementia (RUD) instrument [33], version
RUD Complete 3.1, by interview with the caregiver. This
is a widely used standardized instrument for collecting
resource use data in dementia and has been validated for
use in different care settings, including community-
dwelling patients [34, 35]. Time (in the month before
the baseline visit) was recorded as the total number of
caregiving hours, including the number of hours spent
on basic ADL (e.g., help with eating, getting dressed),
instrumental ADL (iADL; e.g., cooking, shopping), andpatient supervision (i.e., watching the patient to prevent
dangerous events).
Measures of HCRU
Patient and caregiver HCRU (number of outpatient
visits, emergency room [ER; accident and emergency de-
partment] visits, and nights hospitalized) was also
assessed using the RUD instrument [33] for the month
before the baseline visit. HCRU could be for any purpose
and may not have been related to AD dementia or
diabetes.
Statistical analysis
Baseline characteristics of caregivers and patients were
summarized based on non-missing observations. Data
are presented as mean (standard deviation [SD]) or as
numbers and percentages of caregivers/patients. The p-
values presented for comparisons of baseline character-
istics between patient/caregiver diabetes groups were
obtained using Analysis of Variance (ANOVA) for con-
tinuous variables, with country and diabetes status as
factors; and Cochran–Mantel–Haenszel test for categor-
ical variables, with stratification by country.
Descriptive statistics for caregiver burden (ZBI) are pre-
sented as mean (SD), caregiver time measures as median
with interquartile range (Q1–Q3), and HCRU as n (%) of
caregivers/patients using each type of healthcare resource
(i.e., outpatient or ER visits, nights hospitalized).
In order to investigate the possible causal effect of dia-
betes status on outcomes of interest, a propensity score
approach was adopted to adjust for any potential imbal-
ance of the core baseline data between diabetes and
non-diabetes groups. Propensity scores for patient and
caregiver diabetes status were derived separately based
on age, body mass index (BMI), and sex for patients,
and on age and sex for caregivers (ethnicity and care-
giver BMI were not collected in GERAS).
Analyses were performed using regression models ad-
justed for the following covariates to minimize con-
founding: country, age, sex, AD dementia severity at
baseline (mild, moderate, moderately severe/severe), pa-
tient BMI, concomitant use of acetylcholinesterase in-
hibitors, concomitant use of memantine, education
(<8 years, 8–12 years, >12 years), time since AD diagno-
sis, whether the caregiver was living with the patient (no
vs. yes), patient living location (rural vs. urban), living ar-
rangement (living alone; not living alone +married; not
living alone + not married), and propensity score.
The effect of diabetes status on ZBI score at baseline was
assessed using Analysis of Covariance (ANCOVA). Effect of
diabetes on caregiver time was assessed using a generalized
linear model with gamma distribution and log link. Due to
a high number of zero values (i.e., as many patients do not
require help with basic ADL or supervision), the number of
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lyzed using zero-inflated negative binomial regression
models. HCRU variables were analyzed as dichotomized
endpoints using logistic regression.
Results from analyses are presented as absolute differ-
ence, percentage increase, or percentage increase based
on odds ratios with p-values and 95 % CIs for patients/
caregivers with versus without diabetes. The p-values
presented for comparisons between patient/caregiver
diabetes groups were obtained using likelihood ratio sta-
tistics for all measures except requirement for supervi-
sion and caregiver time on basic ADL, where only the
Wald test was available.
To assess the effect of AD dementia severity, second-
ary analyses were conducted using data from the sub-
group with mild/moderate AD dementia (MMSE score
16–26 points).
Sensitivity analyses were performed to assess the effect of
excluding propensity scores and patient BMI (due to the
high level of missing data for BMI) from the main analyses.
All data were analyzed using SAS software Version 9.2
(SAS Institute, Cary, North Carolina, USA).
Results
Comparison: patients with diabetes versus without
diabetes
Of the 1495 patients with AD included in this study, 188
(12.6 %) had diabetes. Most patients with diabetes
(87.8 %) were receiving diabetes medication. Patients with
and without diabetes did not differ significantly in time
since AD diagnosis, MMSE score and AD medication use
(Table 1). Patients with diabetes were less likely to be
married/cohabiting, more likely to be living alone in their
own home, and had fewer years of education than patients
without diabetes (all p < 0.05). Patients with diabetes had a
slightly but significantly higher BMI (mean 26.3 vs.
25.2 kg/m2, p < 0.001) than patients without diabetes.
Caregiver baseline characteristics
Caregivers of patients with diabetes were younger (mean
age 65.0 vs. 67.7 years, p = 0.012) and more likely to be
female (73.9 % vs. 62.8 %, p = 0.005) and the patient’s wife
(37.2 % vs. 33.2 %) or adult child (36.7 % vs. 25.7 %; p =
0.001 for caregiver relationship to the patient), compared
with caregivers of patients without diabetes (Table 1).
Caregiver burden
The overall mean (SD) ZBI total score at baseline was 29.0
(15.07); Table 2. All caregiver time measures showed wide
variation within the patient diabetes groups (Table 2); for
example, although an overall median of 60.0 h was reported
for iADL in the month before baseline, the interquartile
range (Q1–Q3) was 20.0–120.0 h. Analyses were adjusted
for potentially confounding covariates.Figure 1a shows a consistent general effect of in-
creased burden/time requirement for caregivers of pa-
tients with versus without diabetes in the main analysis;
some of these differences were statistically significant. A
trend towards increased ZBI total score was observed
for caregivers of patients with diabetes, along with sig-
nificantly more caregiver time spent on iADL (+16 %; p
= 0.03). Total caregiver time also showed a similar in-
crease for caregivers of patients with diabetes, although
this difference did not reach statistical significance
(Fig. 1a). Many patients with AD dementia, particularly
those with milder severity, do not require supervision or
any caregiver time spent on basic ADL (zero hours for
those two outcomes were reported for more than 25 %
of patients overall; Table 2). Patients with diabetes had a
63 % increase in the odds of requiring supervision com-
pared with patients without diabetes (p = 0.01), although
among those who did require supervision there was no
significant difference in supervision time for patients
with versus without diabetes. The odds of requiring
caregiver time helping with basic ADL, and the number
of hours spent on basic ADL (for those who required
this help), were also higher for patients with versus with-
out diabetes, but these differences did not reach statis-
tical significance (Fig. 1a).
Caregiver and patient HCRU
Outpatient visits were more frequently used by patients
than caregivers: 1204 patients (80.6 %) and 857 caregivers
(57.4 %) overall had one or more outpatient visit in the
month before baseline (Table 2). Less than 5 % of care-
givers and patients overall had ER visits or hospitalizations
during this time (Table 2). No HCRU measures were
significantly affected by patient diabetes status (Fig. 1a).
Comparison: caregivers with versus without diabetes
Overall, 127 caregivers in this analysis had diabetes
(8.5 % of the caregiver population), most of whom
(92.9 %) were receiving diabetes medication.
Caregiver baseline characteristics
Compared with caregivers without diabetes, caregivers
with diabetes were older (mean age 72.4 vs. 66.9 years,
p < 0.001), less likely to be female (54.3 % vs. 65.1 %, p =
0.012), and more likely to be the patient’s husband
(41.7 % vs. 31.3 %, p < 0.001 for caregiver relationship to
the patient) and living with the patient (89.0 % vs.
74.8 %, p < 0.001); Table 3.
Caregiver burden
Again, results for all burden measures were highly vari-
able, both overall and within the different caregiver dia-
betes groups (Table 4).
Table 1 Patient and caregiver characteristics according to diabetes status of the patient with AD dementia
Characteristica Overall N = 1495 Patients with diabetes N = 188 Patients without diabetes N = 1307 P-value
Patients
Age, yearsb 77.6 (7.65) 78.0 (6.97) 77.5 (7.74) 0.137
Sex, n (%) female 819 (54.8) 94 (50.0) 725 (55.5) 0.171
BMI, kg/m2 25.3 (4.07) 26.3 (4.20) 25.2 (4.02) <0.001
Marital status, n (%) 0.019
Married/cohabiting 1076 (72.0) 122 (64.9) 954 (73.0)
Widowed 361 (24.2) 60 (31.9) 301 (23.0)
Divorced/separated 36 (2.4) 2 (1.1) 34 (2.6)
Never married 21 (1.4) 4 (2.1) 17 (1.3)
Living location, n (%) 0.892
Urban 1131 (75.7) 143 (76.1) 988 (95.7)
Rural 363 (24.3) 45 (23.9) 318 (24.3)
Living in own home, n (%) 1428 (95.7) 179 (95.7) 1249 (95.7) 0.220
Living alone in own home, n (%) 253 (17.7) 33 (18.4) 220 (17.6) 0.017
Alcohol consumption, n (%) 885 (61.4) 91 (51.1) 794 (62.9) 0.043
Years of education 10.4 (3.15) 9.5 (2.84) 10.6 (3.17) <0.001
Time since AD diagnosis, years 2.2 (2.23) 2.1 (2.00) 2.3 (2.26) 0.268
Patients with comorbiditiesc, n (%) 1101 (73.6) 188 (100) 913 (69.9) 0.144
Diabetes drug use, n (%) 165 (87.8)
Experienced a fall in last 3 months, n (%) 196 (13.1) 26 (13.8) 170 (13.0) 0.465
MMSE total score (range 0–30) 17.4 (6.34) 17.4 (6.14) 17.4 (6.37) 0.909
Neuropsychological assessment in last
6 months, n (%)
841 (56.4) 108 (57.4) 733 (56.2) 0.499
AD drug use, n (%) 0.750
No AD medications 212 (14.2) 29 (15.4) 183 (14.0)
One AD medication 1121 (75.0) 141 (75.0) 980 (75.0)
Two or more AD medications 162 (10.8) 18 (9.6) 144 (11.0)
Psychiatric/hypnotic drug use, n (%) 393 (26.3) 44 (23.4) 349 (26.7) 0.656
Caregivers
Age, yearsb 67.3 (12.04) 65.0 (12.69) 67.7 (11.91) 0.012
Sex, n (%) female 958 (64.2) 139 (73.9) 819 (62.8) 0.005
Marital status, n (%) 0.403
Married/cohabiting 1316 (88.1) 163 (86.7) 1153 (88.4)
Widowed 38 (2.5) 3 (1.6) 35 (2.7)
Divorced/separated 70 (4.7) 9 (4.8) 61 (4.7)
Never married 69 (4.6) 13 (6.9) 56 (4.3)
Relationship to the patient, n (%) 0.001
Wife 503 (33.7) 70 (37.2) 433 (33.2)
Husband 481 (32.2) 39 (20.7) 442 (33.9)
Child 405 (27.1) 69 (36.7) 336 (25.7)
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Table 1 Patient and caregiver characteristics according to diabetes status of the patient with AD dementia (Continued)
Friend 20 (1.3) 2 (1.1) 18 (1.4)
Other 84 (5.6) 8 (4.3) 76 (5.8)
Caregiver lives with the patient, n (%) 1135 (76.0) 141 (75.0) 994 (76.2) 0.781
Caregivers with medical conditionsc, n (%) 875 (58.6) 105 (55.9) 770 (59.0) 0.181
AD Alzheimer’s disease, BMI body mass index, MMSE Mini-Mental State Examination
aData are presented as mean (SD) unless indicated otherwise. Percentages reported are for patients/caregivers with data available for each specific variable.
Missing data for patients (overall): no missing data for age, sex, comorbidities, diabetes drug use, MMSE total score, AD drug use, psychiatric/hypnotic drug use;
amount of missing data for other variables were BMI (n = 220), marital status (n = 1), living location (n = 1), living in own home (n = 3), living alone in own home
(n = 67), alcohol consumption (n = 54), years of education (n = 6), time since AD diagnosis (n = 1), experienced a fall (n = 2), neuropsychological assessment (n = 3).
Missing data for caregivers (overall) was n = 2 for all variables except medical conditions (n = 1; caregiver diabetes status not collected)
bThe Case Report Form collected only birth year data, thus the missing month and day were imputed with 15 July. Age is the year part of the difference between
the date of Informed Consent and the imputed birth date
cData include the presence of diabetes
P-values are for the comparison between patient diabetes groups (ANOVA for continuous variables, with country and diabetes status as factors, and Cochran-
Mantel-Haenszel test for categorical variables, with stratification by country)
P-values indicating statistically significant differences between patient diabetes groups (p < 0.05) are highlighted in bold type
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cally significant effects on burden or caregiver time, al-
though a trend toward lower burden in caregivers with
versus without diabetes was observed (Fig. 2a).
Caregiver HCRU
Although 636 caregivers overall (42.6 %) had no out-
patient visits (Table 4), caregivers with diabetes had a
91 % increase in the odds of having outpatient visits
compared with caregivers without diabetes (p = 0.01;
Fig. 2a). The odds of having ER visits or of being hospi-
talized did not differ between caregiver diabetes groups
(Fig. 2a).
Subgroup analysis: patient population with mild/
moderate AD dementia only
To provide an assessment of the effect of AD dementia
severity on the results, a secondary analysis was per-
formed based on a subgroup of patients with mild/mod-
erate AD dementia (N = 985). As seen in the main
analysis, results for all burden/time measures were
highly variable, both overall and within the different pa-
tient (Table 2) and caregiver (Table 4) diabetes groups.
Patients with mild/moderate AD dementia were less
likely to require supervision than those in the overall
population with AD dementia (more than 50 % of pa-
tients with mild/moderate AD dementia had zero values
for caregiver supervision hours [median supervision time
was 0 h; Table 2]).
A total of 799 patients (81.2 %) and 574 caregivers
(58.3 %) had one or more outpatient visit in the month
before baseline (Tables 2 and 4). Less than 4 % of pa-
tients and caregivers overall had ER visits or hospitaliza-
tions (Tables 2 and 4).
Neither patient nor caregiver diabetes status showed clear
or significant effects on burden, caregiver time, or caregiver
or patient HCRU in analyses based on the patient popula-
tion with mild/moderate AD dementia (Fig. 1b).As seen for the total AD dementia severity population,
caregivers with diabetes had a 79 % increase in the odds
of having outpatient visits compared with caregivers
without diabetes (p = 0.04), but the odds of having ER
visits or of being hospitalized did not differ between
caregiver diabetes groups (Fig. 2b).
Sensitivity analyses
Sensitivity analyses showed that results were qualitatively
unchanged by removing propensity scores and patient
BMI, indicating that the conclusions of the main ana-
lyses were robust.
Discussion
This analysis of a real-world population of community-
dwelling patients with AD and their informal caregivers
found that caregiver time spent on iADL and require-
ment for supervision were significantly higher for care-
givers of patients with diabetes versus without diabetes.
Although a consistent general increase in caregiver time
on basic ADL, iADL, and total caregiver time was ob-
served for caregivers of patients with diabetes, this effect
was only statistically significant for iADL, possibly due
to the variability within the dataset.
These results for caregiver time are in line with those
of Langa et al. [24], who found that elderly Americans
with diabetes required more time for informal care than
those without diabetes, and indicate that this effect is
also observed in patients with AD dementia who gener-
ally require more care than the general population of a
similar age group.
The impact of patient diabetes status on caregiver burden
was more evident for objective measures (caregiver time)
than the subjective measure, ZBI score. A trend towards in-
creased ZBI score was observed for caregivers of patients
with versus without diabetes, but this small difference (+1.6)
is unlikely to have significant real-life impact for the care-
giver. This is in line with previous data suggesting that
Table 2 Caregiver burden/time, and caregiver and patient HCRU according to patient diabetes status (descriptive statistics)
Total AD dementia severity population Mild/moderate AD dementia
Parameter Overall
N = 1495
Patients with
diabetes N = 188
Patients without
diabetes N = 1307
Overall
N = 985
Patients with
diabetes N = 119
Patients without
diabetes N = 866
Caregivers
ZBI score, mean (SD) 29.0
(15.07)
30.8
(15.37)
28.8
(15.01)
26.6
(14.71)
28.1
(14.81)
26.4
(14.69)
Total caregiver time (hours),
median (Q1-Q3)
105.0
(30.0–330.0)
122.5
(45.0–415.0)
105.0
(30.0–322.0)
75.0
(20.0–180.0)
84.0
(21.0–194.0)
70.0
(20.0–180.0)
Hours on basic ADL, median
(Q1-Q3)
6.0
(0.0–60.0)
15.0
(0.0–60.0)
5.0
(0.0–60.0)
0.0
(0.0–30.0)
0.0
(0.0–24.0)
0.0
(0.0–30.0)
Hours on iADL, median
(Q1-Q3)
60.0
(20.0–120.0)
60.0
(22.5–120.0)
60.0
(20.0–120.0)
46.5
(15.0–90.0)
56.0
(15.0–90.0)
45.0
(14.0–90.0)
Hours on supervision, median (Q1-Q3) 8.0
(0.0–120.0)
30.0
(0.0–206.0)
4.0
(0.0–104.5)
0.0
(0.0–30.0)
0.0
(0.0–60.0)
0.0
(0.0–30.0)
Caregiver outpatient visits, n (%)
No visits 636 (42.6) 80 (42.6) 556 (42.6) 410 (41.7) 46 (38.7) 364 (42.1)
1 visit 401 (26.9) 45 (23.9) 356 (27.3) 270 (27.4) 31 (26.1) 239 (27.6)
2 visits 199 (13.3) 22 (11.7) 177 (13.6) 134 (13.6) 15 (12.6) 119 (13.8)
3 visits 97 (6.5) 14 (7.4) 83 (6.4) 62 (6.3) 9 (7.6) 53 (6.1)
>3 visits 160 (10.7) 27 (14.4) 133 (10.2) 108 (11.0) 18 (15.1) 90 (10.4)
Caregivers with ≥1 ER visit in past
month, n (%)
45 (3.0) 2 (1.1) 43 (3.3) 28 (2.8) 1 (0.8) 27 (3.1)
Caregivers with ≥1 night hospitalization
in past month, n (%)
34 (2.3) 2 (1.1) 32 (2.5) 24 (2.4) 2 (1.7) 22 (2.5)
Patients
Patient outpatient visits, n (%)
No visits 289 (19.4) 26 (13.8) 263 (20.2) 185 (18.8) 19 (16.0) 166 (19.2)
1 visit 415 (27.8) 43 (22.9) 372 (28.5) 275 (27.9) 26 (21.8) 249 (28.8)
2 visits 315 (21.1) 41 (21.8) 274 (21.0) 211 (21.4) 22 (18.5) 189 (21.8)
3 visits 134 (9.0) 22 (11.7) 112 (8.6) 90 (9.1) 13 (10.9) 77 (8.9)
>3 visits 340 (22.8) 56 (29.8) 284 (21.8) 223 (22.7) 39 (32.8) 184 (21.3)
Patients with ≥1 ER visit in past month,
n (%)
43 (2.9) 7 (3.7) 36 (2.8) 24 (2.4) 4 (3.4) 20 (2.3)
Patients with ≥1 night hospitalization
in past month, n (%)
62 (4.2) 14 (7.4) 48 (3.7) 36 (3.7) 7 (5.9) 29 (3.4)
AD Alzheimer’s disease, ADL activities of daily living, ER emergency room, HCRU health care resource use, iADL instrumental ADL, Q quartile, SD standard deviation,
ZBI Zarit Burden Interview
Percentages reported are for caregivers and patients with data available for each specific variable. Missing data for the total AD dementia population (overall
diabetes status) were n = 2 for all measures (for caregivers and patients) except ZBI score (n = 10). Missing data based on the population with mild/moderate AD
dementia were n = 1 for all measures (for caregivers and patients) except ZBI score (n = 7)
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givers of community-dwelling frail elderly patients in Japan,
measured using the Japanese version of the ZBI [23]. A
comparative analysis also found caring for patients with can-
cer or dementia was associated with greater physical strain
and emotional stress than caring for those with diabetes or
for frail elderly people [36]. It is possible that the burden of
caring for a person with AD dementia subsumes any added
burden associated with diabetes. Feil et al. [22] reported a
high level of subjective burden (according to the 4-item ver-
sion of the ZBI) in caregivers of patients with both dementia
and diabetes, but the sample size was small (N= 21) and theabsence of a comparator group meant that it was not
possible to assess the extent to which diabetes added to the
burden of caring for someone with dementia alone.
Patient and caregiver HCRU was unaffected by
patient diabetes status. However, HCRU data were
based on the month before baseline only. Meaningful
between-group differences may be observed over a
longer period of time of prospective data capture, par-
ticularly on hospitalizations and ER visits which are
expected to have a generally low base rate over a single
month. Caregiver HCRU has previously been shown to be
affected by several aspects of AD dementia [37], and our
AB
Fig. 1 Caregiver burden/time, and caregiver and patient HCRU according to patient diabetes status. a Total AD dementia population. b Mild/
moderate AD dementia population. AD Alzheimer’s disease, ADL activities of daily living, CI confidence interval, ER emergency room, HCRU health
care resource use, ZBI Zarit Burden Interview. Data are presented as absolute difference or % increase with 95 % CIs for patients with versus
without diabetes. HCRU measures are reported as the percentage increase in the odds of having outpatient or ER visits or of being hospitalized.
P-values (obtained using likelihood ratio statistics for all measures except requirement for supervision and caregiver time on basic ADL, where
only the Wald test was available) are for the comparison between patient diabetes groups. *As ZBI data are presented as absolute difference it
was not possible to include this measure in the Forest plot with the effects of the other endpoints, which are presented as % increase
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Table 3 Caregiver characteristics according to caregiver diabetes status
Characteristica Overall
N = 1494b
Caregivers with
diabetes N = 127
Caregivers without
diabetes N = 1367
P-value
Caregiver characteristics
Age, yearsc 67.3 (12.04) 72.4 (9.67) 66.9 (12.13) <0.001
Sex, n (%) female 958 (64.2) 69 (54.3) 889 (65.1) 0.012
Marital status, n (%) 0.022
Married/cohabiting 1316 (88.1) 123 (96.9) 1193 (87.3)
Widowed 38 (2.5) 1 (0.8) 37 (2.7)
Divorced/separated 70 (4.7) 1 (0.8) 69 (5.1)
Never married 69 (4.6) 2 (1.6) 67 (4.9)
Relationship to the patient, n (%) <0.001
Wife 503 (33.7) 50 (39.4) 453 (33.2)
Husband 481 (32.2) 53 (41.7) 428 (31.3)
Child 405 (27.1) 13 (10.2) 392 (28.7)
Friend 20 (1.3) 2 (1.6) 18 (1.3)
Other 84 (5.6) 9 (7.1) 75 (5.5)
Caregiver lives with the patient, n (%) 1135 (76.0) 113 (89.0) 1022 (74.8) <0.001
Caregivers with medical conditionsd, n (%) 127 (100) 748 (54.7) 875 (58.6) 0.178
Diabetes drug use, n (%) 118 (92.9)
aData are presented as mean (SD) unless indicated otherwise. Percentages reported are for caregivers with data available for each specific variable. Missing data
(overall) were n = 1 for all variables, except medical conditions and diabetes drug use (no missing data)
bDiabetes status was unknown for one caregiver, thus N = 1494
cThe Case Report Form collected only birth year data, thus the missing month and day were imputed with 15 July. Age is the year part of the difference between
the date of Informed Consent and the imputed birth date
dData include the presence of diabetes
P-values are for the comparison between caregiver diabetes groups (ANOVA for continuous variables, with country and diabetes status as factors, and Cochran–
Mantel–Haenszel test for categorical variables, with stratification by country)
P-values indicating statistically significant differences between caregiver diabetes groups (p < 0.05) are highlighted in bold type
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and caregiver diabetes in this population.
Analyses based on the subgroup of patients with mild/
moderate AD dementia, found no consistent effects of
patient diabetes status on burden, caregiver time, or care-
giver or patient HCRU, suggesting that differences between
the diabetes groups in the overall population were driven by
the patients with moderately severe/severe AD dementia.
This finding is consistent with our prior analysis showing
that better patient functioning is associated with lower care-
giver burden and fewer supervision hours in GERAS [21],
although we did not adjust for functional status in our ana-
lysis. As patients with moderately severe/severe AD demen-
tia would generally function at a lower level than patients
with mild/moderate AD dementia, they would consequently
be unlikely to be able to manage their own diabetes, thus
increasing the time required from the caregiver. Caregivers
of patients with mild/moderate AD dementia may also
provide most care around mealtimes and bed times, which
may coincide with any requirement for them to assist with
diabetes treatment and blood glucose monitoring.
In the main analyses, time and burden were unaffected
by caregiver diabetes status; again caregiver time was
based on the month before baseline only (ZBI scorereflected the subjective burden reported at the baseline
visit). We had anticipated that caregivers with diabetes
would report greater burden than those without dia-
betes, due to the added burden of managing their own
diabetes along with the patient’s AD dementia; however,
our results did not support this hypothesis. The reasons
are unclear, but may be related to the small number of
caregivers who had diabetes in this study. It is also pos-
sible that caregivers who have diabetes themselves and
are already comfortable with managing their condition
do not perceive the management of the patient’s diabetes
as a significant additional burden; however, the study
sample size was too small to allow a further subanalysis.
Caregivers with diabetes had increased odds of having
outpatient visits for their own health care than caregivers
without diabetes, which could be expected for people with
chronic conditions. Other aspects of caregiver HCRU were
not associated with caregiver diabetes status, regardless of
the dementia severity of the AD patients under their care.
Strengths
We used data from a large prospective observational study
of community-dwelling patients with AD across a wide
range of dementia severity groups in three European
Table 4 Caregiver burden, time, and HCRU according to caregiver diabetes status (descriptive statistics)
Parametera Total AD dementia severity population Mild/moderate AD dementia
Overall
N = 1494b
Caregivers with
diabetes N = 127
Caregivers without
diabetes N = 1367
Overall
N = 985
Caregivers with
diabetes N = 88
Caregivers without
diabetes N = 897
ZBI score 29.0
(15.07)
26.7
(14.82)
29.2
(15.08)
26.6
(14.71)
24.8
(14.29)
26.8
(14.74)
Total caregiver time, hours 105.0
(30.0–330.0)
120.0
(31.0–375.0)
105.0
(30.0–330.0)
75.0
(20.0–180.0)
82.5
(30.0–210.0)
75.0
(18.0–180.0)
Hours on basic ADL 6.0
(0.0–60.0)
0.0
(0.0–60.0)
7.3
(0.0–60.0)
0.0
(0.0–30.0)
0.0
(0.0–15.0)
0.0
(0.0–30.0)
Hours on iADL 60.0
(20.0–120.0)
60.0
(30.0–120.0)
60.0
(20.0–120.0)
46.5
(15.0–90.0)
48.8
(15.5–90.0)
46.5
(15.0–90.0)
Hours on supervision 8.0
(0.0–120.0)
15.0
(0.0–240.0)
8.0
(0.0–120.0)
0.0
(0.0–30.0)
1.3
(0.0–60.0)
0.0
(0.0–30.0)
Caregiver outpatient visits, n (%)
No visits 636 (42.6) 35 (27.6) 601 (44.0) 410 (41.7) 24 (27.3) 386 (43.1)
1 visit 401 (26.9) 29 (22.8) 372 (27.2) 270 (27.4) 24 (27.3) 246 (27.5)
2 visits 199 (13.3) 34 (26.8) 165 (12.1) 134 (13.6) 22 (25.0) 112 (12.5)
3 visits 97 (6.5) 10 (7.9) 87 (6.4) 62 (6.3) 7 (8.0) 55 (6.1)
>3 visits 160 (10.7) 19 (15.0) 141 (10.3) 108 (11.0) 11 (12.5) 97 (10.8)
Caregivers with ≥1 ER visit in past
month, n (%)
45 (3.0) 3 (2.4) 42 (3.1) 28 (2.8) 2 (2.3) 26 (2.9)
Caregivers with ≥1 night
hospitalization in past month, n (%)
34 (2.3) 5 (3.9) 29 (2.1) 24 (2.4) 5 (5.7) 19 (2.1)
AD Alzheimer’s disease, ADL activities of daily living, ER emergency room, HCRU health care resource use, iADL instrumental ADL, ZBI Zarit Burden Interview
aData are presented as mean (SD) or median (Q1–Q3), unless indicated otherwise. Percentages reported are for caregivers with data available for each specific
variable. Missing data for the total AD dementia population (overall diabetes status) were n = 1 for all measures (for caregivers and patients) except ZBI score
(n = 9). Missing data based on the population with mild/moderate AD dementia were n = 1 for all measures (for caregivers and patients) except ZBI score (n = 7)
bDiabetes status was unknown for one caregiver, thus N = 1494
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the effects of diabetes on burden, as reported by caregivers
of these patients, in a real-world setting.
To our knowledge, this is the first study to directly
assess whether diabetes affects burden, time spent on
caregiving, or HCRU in caregivers of patients with
AD. Our findings add to those from other studies that
have identified many factors that influence burden in
caregivers of patients with AD [21, 38, 39]. Although
we found no significant effect of patient diabetes on
caregiver burden as assessed by ZBI, there was an in-
crease in caregiver time requirement for patients with
versus without diabetes.
Several standard measures of caregiver burden were
assessed, including the well-recognized ZBI and care-
giver time and HCRU were assessed using the standard-
ized RUD instrument.
Limitations
Although our study provides valuable new data, it has
several limitations which provide a possible focus for fu-
ture studies.
This was a post-hoc exploratory analysis, and a cross-
sectional assessment of baseline data. Results may be
different if a longitudinal perspective were to be used,and this would also allow an assessment of the effect of
diabetes on caregiver burden and patient and caregiver
HCRU over time. It would also identify whether the
early differences in caregiver time measures translate to
increased perceived burden recorded using the ZBI
measure over a longer period.
HCRU information for the month prior to enrollment
was based on caregivers’ report only and did not include
information from medical records or claims data.
The self-reporting of diabetes status (or caregiver-
reporting for some patients) in the GERAS study may
limit the reliability of the information provided as the
use of self-reported diabetes is generally considered to
underestimate the actual prevalence, which includes a
proportion of undiagnosed cases [40]. However, our pa-
tient diabetes prevalence of 12.6 % is in line with the
13–14 % seen in the largest studies reviewed by Bunn
et al. [10] regarding diabetes prevalence in people with
dementia, although reported prevalences ranged from 6
to 39 % [10]; diabetes prevalence data in this review
were obtained from medical records and/or clinical
examination. The older age of the patients in our study
and/or presence of AD, may explain the expected
higher diabetes prevalence in patients than in caregivers
(12.6 and 8.5 %, respectively). Furthermore, we did not
AB
Fig. 2 Caregiver burden/time, and caregiver and patient HCRU according to caregiver diabetes status. a Total AD dementia population. b Mild/
moderate AD dementia population. AD Alzheimer’s disease, ADL activities of daily living, CI confidence interval, ER emergency room, HCRU health
care resource use, ZBI Zarit Burden Interview. Data are presented as absolute difference or % increase with 95 % CIs for caregivers with versus
without diabetes. HCRU measures are reported as the percentage increase in the odds of having outpatient or ER visits or of being hospitalized.
P-values (obtained using likelihood ratio statistics for all measures except requirement for supervision and caregiver time on basic ADL, where
only the Wald test was available) are for the comparison between caregiver diabetes groups. *As ZBI data are presented as absolute difference it
was not possible to include this measure in the Forest plot with the effects of the other endpoints, which are presented as % increase
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type 2, so are unable to confirm whether these pro-
portions are in line with those seen typically for the
different diabetes types. Links between cognition in
AD dementia and both types of diabetes have been
reported [41].
No information was obtained regarding the type or dos-
age of glucose-lowering medications or the level of dia-
betes control. It is possible that differences in burden/time
existed regarding, for example, whether or not patients
were receiving insulin and/or the amount of monitoring
needed. Several aspects of diabetes care have been reported
as being difficult to perform or supervise due to the pa-
tient’s dementia, particularly adherence to diabetes-related
exercise regimes and dietary requirements [22]. Informal
caregiver time was higher for elderly patients with diabetes
who used insulin, compared with those taking no medica-
tion or oral medication in the study by Langa et al. [24].
However, although diabetes itself did not independently
predict burden in the study by Hirakawa et al. [23],
community-dwelling frail elderly patients with diabetes
who were not taking medication required a higher degree
of care compared with those taking diabetes medication or
those without diabetes; these patients (with diabetes and no
medication) were also more likely to suffer from hyperten-
sion and dementia. Patients with diabetes who were taking
insulin used more transportation (and therefore required
more time) than those on no or oral medication [23]. Ef-
fects of caregiver diabetes status on burden may also vary
depending on their diabetes type, treatment, and severity.
Treating complications associated with diabetes may
also increase caregiver burden. As data regarding spe-
cific diabetes-related complications were not collected in
the GERAS study, we were also unable to assess whether
such complications influenced our results. Increased
emotional burden has previously been shown in care-
givers of diabetes patients with foot ulcers [42].
Suggestions for future research
This study provides new data on the overall effect of dia-
betes on subjective burden, time and HCRU in care-
givers of patients with AD. Future research should
include longitudinal analyses, assessing the change in
these factors over time, and could consider the influence
of various aspects of diabetes in order to inform appro-
priate support that could be given to patients and care-
givers. Several diabetes-related issues (e.g., restricting
intake of inappropriate foods, using a glucose meter, and
providing assistance with oral medication) have been as-
sociated with objective burden in caregivers of patients
with both schizophrenia and diabetes [43], and with sub-
jective burden in caregivers of patients with both de-
mentia and diabetes [22]. It is also possible that less
time-consuming options for diabetes treatment andmonitoring may offer a potential way to reduce burden,
by reducing the time spent by the caregiver on iADL.
This may include simplified treatment regimens, such as
taking fewer medications, less frequent injections, or use
of medical devices that allow for more automated moni-
toring and insulin administration. Such measures may
also improve medication adherence and diabetes control
in patients with dementia, who are less likely to receive
their recommended annual monitoring for diabetes and
may have poorer access to diabetes services [10, 44, 45].
Potential effects of other comorbidities in both patients
and caregivers could also be examined: observational
studies are likely to show greater heterogeneity in co-
morbidity data, compared with those from randomized
clinical trials, and are therefore best suited to this type
of analysis. The effect on caregiver health of caring for
patients with diabetes and AD could also be
investigated.
Further research, such as that identified, could provide
opportunities to guide appropriate caregiver support
strategies and policies. Improved support and education
regarding diabetes care adjustments could potentially
lessen caregiver burden [22]. As well as simplifying the
patient’s medication as much as possible, the effects of
additional help, such as assistance from professional
caregivers or other family members to provide respite
for the primary caregiver, also require consideration.
Conclusions
Data from our study indicate that caregiver time spent
on iADL and requirement for supervision was higher for
caregivers of patients with AD with diabetes versus with-
out diabetes. However, HCRU by both caregivers and
patients in the month prior to study enrollment was un-
affected by patient diabetes status.
Considering that this investigation was a cross-sectional
analysis, future longitudinal studies assessing change in
caregiver burden over time by patient diabetes status will
help clarify the cumulative impact of diabetes and AD de-
mentia on caregiver burden. Identifying factors that influ-
ence burden may also help to inform appropriate support
that could be given to patients and caregivers.
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